Patient Population, Inclusion Requirements During Phase 2 Trial Assessing Niraparib for Uterine Serous Carcinoma Treatment

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

During this interview, Frimer discussed what the patient population size and inclusion requirements were during the phase 2 trial assessing niraparib, as well as how patients were selected.

Marina Frimer: So, the goal for the recruitment for this study is 45 total patients, and the patients are selected on the inclusion criteria: the women have uterine serious cancer, they're stage 3 or 4 disease or those who have recurrent disease but are deemed platinum sensitive after primary platinum treatment.